Dr. Yehuda Z. Lebowicz, MD

Dr. Lebowicz practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Dr. Lebowicz's NPI, 1598939159, was assigned on April 15, 2008. Dr. Lebowicz graduated from State University of New York at Stony Brook, School of Medicine in 2002. Dr. Lebowicz holds Pennsylvania license 466778.

Dr. Lebowicz's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Dr. Lebowicz's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Dr. Lebowicz is also affiliated with UPMC Passavant-McCandless. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Dr. Lebowicz to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lebowicz practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lebowicz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Lebowicz's licenses on file in 3 states: Pennsylvania, New York and West Virginia.

CMS data shows 779 Medicare services from Dr. Lebowicz across 7 procedure codes in 2024, for 235 Medicare patients. Medicare paid $67,585 for them.

CMS counts 235 Medicare patients who saw Dr. Lebowicz in 2024. The largest group is 65 to 74, with 110 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lebowicz's median patient age at 71, with 50% women.

In 2024, Dr. Lebowicz wrote 2,001 Medicare Part D claims for 324 patients. 79% of them were for generic drugs. CMS names the drug for 1,634 of them, across 39 drugs with 11 or more claims each, at $2,617,165 in total drug cost. In 2023, CMS named 1,522 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Dr. Lebowicz for performance year 2024, reported as part of a group. Dr. Lebowicz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 17 papers to Dr. Lebowicz, published from 2013 to 2021. 2016 was the busiest year, with 5. The most frequent topics are Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols and Immunotherapy. Dr. Lebowicz has published most often in J Investig Med High Impact Case Rep. Dr. Lebowicz's most frequent co-authors are Yousef Khelfa, MD, Mohamed F. Alsharedi, MD and Hassaan Yasin, MD.

CMS Open Payments shows 278 general payments to Dr. Lebowicz from 24 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 47% of the total. Alexion Pharmaceuticals, Inc. paid the most, $45,484.

Dr. Lebowicz graduated from State University of New York at Stony Brook, School of Medicine in 2002.